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Expression profiles represent new molecular tools that are useful to characterize the
successive steps of tumor progression and the prediction of recurrence or
chemotherapy response. In this study, we have used quantitative proteomic analysis
to compare different stages of colorectal cancer. A combination of laser
microdissection, OFFGEL separation, iTRAQ labeling, and MALDI-TOF/TOF MS was
used to explore the proteome of 28 colorectal cancer tissues. Two software packages
were used for identification and quantification of differentially expressed proteins:
Protein Pilot and iQuantitator. Based on ∼1,190,702 MS/MS spectra, a total of 3138
proteins were identified, which represents the largest database of colorectal cancer
realized to date and demonstrates the value of our quantitative proteomic approach.
In this way, individual protein expression and variation have been identified for each
patient and for each colorectal dysplasia and cancer stage (stages I–IV). A total of
555 proteins presenting a significant fold change were quantified in the different
stages, and this differential expression correlated with immunohistochemistry results
reported in the Human Protein Atlas database. To identify a candidate biomarker of
the early stages of colorectal cancer, we focused our study on secreted proteins. In
this way, we identified olfactomedin-4, which was overexpressed in adenomas and in
early stages of colorectal tumors. This early stage overexpression was confirmed by
immunohistochemistry in 126 paraffin-embedded tissues. Our results also indicate
that OLFM4 is regulated by the Ras-NF-κB2 pathway, one of the main oncogenic
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